AMSBIO has launched a range of ELISA Host Cell Protein (HCP) detection kits that allow you to detect the presence of host cell protein impurities in your therapeutic at any phase of your product development.Host cells used as expression systems in biopharmaceutical products contain hundreds to thousands of HCPs. It is crucial to sufficiently remove HCPs from your biologic early, as high concentrations can affect the safety and efficacy of your drug. The FDA has regulated that HCPs should be reduced to low levels.The new HCP detection kits from AMSBIO are based on a sandwich ELISA…
PredictImmune Announces New ‘Framework Agreement’ with Cambridge Enterprise to Allow Future Expansion of Original IP License to Expand its Commercial Product Pipeline; Extending the Benefits of Prognostic Testing to Include Systemic Lupus Erythematosus (SLE)
The agreement will enable PredictImmune to broaden its product range through the development and commercialisation of a prognostic test for SLE
Cambridge, UK, 19 September 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-…
17 September 2019
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, has participated in the £195 million ($240 million) Series C funding round raised by CMR Surgical, the Cambridge-based company developing, manufacturing and marketing the next-generation surgical robotic system, Versius®. CIC was an early investor in CMR Surgical having first invested in the company’s Series A round in 2016. It has continued to provide financial support and guidance, enabling the realisation of the…
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD) after a successful bid led by Eastern AHSN and Cambridge University Hospital Partners.
The Cambridge-based hub, to be known as G.I. Know, will be one of seven hubs set up across the UK to speed up research for new medicines and treatments, support quicker diagnoses and potentially save lives.
G.I. Know will work with patients, industry, academia and the health service to transform our understanding of inflammatory bowel disease, drive improvements in…
Cambridge, UK/MA, September 11 2019: Cedilla Therapeutics and o2h Discovery are pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeutics, a Third Rock backed biotech company based in the Cambridge MA.
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.
o2h is pleased to collaborate with Cedilla, to support…
In the latest of a string of senior appointments, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has recruited Consultant Pharmaceutical Physician, Susan Tansey.
Dr Tansey joins Boyds with more than 20 years’ experience in rare disease clinical trials. A paediatrician specialising in respiratory paediatrics and neonatology, Susan joined the pharmaceutical industry in 1998 and has worked in clinical development across several therapeutic areas, including vaccine research.
Previously, Susan was Vice President and…
Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The…
Sandwich, Kent, September 9 2019 – The Chairman of Discovery Park, a thriving high-quality science park playing a key role in the South East of England’s life sciences community, will be addressing important drivers in the development of the Park at a series of conferences in the Autumn. At events organized by CRACK IT, Life Sciences Integrates, and Cancer Research UK Martino Picardo is looking forward to talking about his experience in open innovation, pre-competitive collaboration and entrepreneurship. Activities in these areas are part of the growth strategy for Discovery Park and its…
Cambridge, UK, 9th September 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, today announced the appointment of Dr. Jane Osbourn, OBE as Chair of the Board. In addition to this role, Dr. Osbourn will become a Member of the Scientific Advisory Board and support the Company’s executive team in therapeutic program selection, industrial partner development, mentoring and investor relations.
Dr. Osbourn has over 30 years’ experience in biologics discovery and development. Most recently, she was Vice President for Research and Development and Site…
Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The…